Abstract:Abstract Background Porcine circovirus type 2 (PCV2) is the causative agent of postweaning multisystemic wasting syndrome, and is associated with a number of other diseases. PCV2 is widely distributed in most developed swine industries, and is a severe economic burden. With an eye to developing an effective, safe, and convenient vaccine against PCV2-associated diseases, we have constructed a recombinant Bacillus subtilis strain ( B. subtilis -Cap) that expresses the PCV2 capsid protein (Cap). Methods Electroporation of a plasmid shuttle vector encoding the PCV2 Cap sequence was use to transform Bacillus subtilis . Flow cytometry was used to evaluate in vitro bone marrow derived dendritic cell (BM-DC) maturation and T cell proliferation induced by B. subtilis -Cap. Orally inoculated piglets were used for in vivo experiments; ELISA and western blotting were used to evaluate B. subtilis -Cap induced PCV2-specific IgA and IgG levels, as well as the secretion of cytokines and the expression of Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9). Results We evaluated the immune response to B. subtilis -Cap in vitro using mouse BM-DCs and in vivo using neonatal piglets orally inoculated with B. subtilis -Cap. Our results showed that the recombinant B. subtilis -Cap activated BM-DCs, significantly increased co-stimulatory molecules (CD40 and CD80) and major histocompatibility complex II, and induced allogenic T cells proliferation. Piglets immunized with B. subtilis -Cap had elevated levels of PCV2-specific IgA in the mucosal tissues of the digestive and respiratory tract, and PCV2-specific IgG in serum ( P < 0.05 or P < 0.01). Ileal immunocompetent cells, such as the IgA-secreting cells ( P < 0.01), intestinal intraepithelial lymphocytes (IELs) ( P < 0.01), CD3 + T lymphocytes ( P < 0.01) and CD4 + T lymphocytes ( P < 0.01) increased significantly in the B. subtilis -Cap immunized piglets. Additionally, B. subtilis -Cap inoculation resulted in increased the expression of TLR2 and TLR9 ( P < 0.01), and induced the secretion of cytokines IL-1β, IL-6, interferon-γ, and β-defensin 2 ( P < 0.01). Conclusions We constructed a prototype PCV2 vaccine that can be administered orally and elicits a more robust humoral and cellular immunity than inactivated PCV2. B. subtilis -Cap is a promising vaccine candidate that is safe, convenient, and inexpensive. Further in vivo research is needed to determine its full range of efficacy in pigs. Graphical abstract

Study on the Nucleotide Vaccine Immune Effect of Porcine Circovirus Type 2 Virus

Immunogenicity of porcine circovirus type 2 nucleic acid vaccine containing CpG motif for mice

Protective Immunity Against Porcine Circovirus 2 by Vaccination with ORF2-based DNA and Subunit Vaccines in Mice.

Immune Response Induced by Recombinant Adenoviruses Expressing ORF2 and ORF1-2 Fusion Gene of PCV2

Evaluation of a Virus-like Nanoparticle Porcine Circovirus Type-2 (PCV2) Capsid Protein Fused with the Pig Immunoglobulin Fc Fragment As a Novel Vaccine Candidate Against PCV2 in Mice

In Vivo Characterization of Chimeric PCV DNA Clones Containing Heterogeneous Capsid Protein Nuclear Localization Signals (NLS).

Humoral and Cellular Immune Responses Induced by Bivalent DNA Vaccines Expressing Fusion Capsid Proteins of Porcine Circovirus Genotypes 2a and 2b

A porcine circovirus type 2d-based virus-like particle vaccine induces humoral and cellular immune responses and effectively protects pigs against PCV2d challenge

Genetic and Immunogenicity Analysis of Porcine Circovirus Type 2 Strains Isolated in Central China

Both recombinant Bacillus subtilis Expressing PCV2d Cap protein and PCV2d-VLPs can stimulate strong protective immune responses in mice

Immunogenicity and Immunoprotection of PCV2 Virus-like Particles Incorporating Dominant T and B Cell Antigenic Epitopes Paired with CD154 Molecules in Piglets and Mice

Characterization and potential use of truncated PCV2 capsid protein and its polyclonal antibody for diagnosis of PCV2 infections.

Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2

The Construction of PCV2 DNA Vaccine and Its Immune Response in Mouse

Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2

Expression and immunogenicity analysis of the capsid proteins of porcine circovirus types 2 to 4

Construction of a novel porcine circovirus type 2 infectious clone as a basis for the development of a PCV2 iDNA vaccine

Epidemiological Analysis From 2018 to 2020 in China and Prevention Strategy of Porcine Circovirus Type 2

A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia

Cloning and Prokaryotic Expression of the ORF2 Gene Fragment of Porcine Circovirus Type 2

Prokaryotic Expression and Antigenic Analysis of the Capsid Protein Porcine Circovirus Type 2